Pharmacometrics: Opportunity for reducing disease burden in the developing world: The case of Africa

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 8, 2013, Pages

  Pillai, G ^a   Davies, G ^b   Denti, P ^c   Steimer, J L ^d   McIlleron, H ^c   Zvada, S ^c   Chigutsa, E ^c   Ngaimisi, E ^e   Mirza, F ^a   Tadmor, B ^f   Holford, N H G ^g  

^a Novartis Pharma AG   (Switzerland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NOVARTIS PHARMA AG   (Switzerland)

^e MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; STAVUDINE;

AFRICA; ARTICLE; DEVELOPING COUNTRY; DRUG DOSE REDUCTION; DRUG MARKETING; DRUG USE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS;

EID: 84883327533     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.45     Document Type: Article

References (11)

1. Makinson, A., Moing, V.L., Kouanfack, C., Laurent, C. & Delaporte, E. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin. Drug Saf. 7, 283-293 (2008).
2. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. & Peck, C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11, 439-446 (2002).
3. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
4. Zhang, L., Pfister, M. & Meibohm, B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 10, 552-559 (2008).
5. Holford, N. Dosing in children. Clin. Pharmacol. Ther. 87, 367-370 (2010).
6. Pollock, L. et al. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J. Antimicrob. Chemother. 64, 1251-1259 (2009).
7. Barnes, K.I., Little, F., Smith, P.J., Evans, A., Watkins, W.M. & White, N.J. Sulfadoxinepyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80, 582-596 (2006).
8. Ashley, E.A. et al. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 50, 2281-2285 (2006).
9. Nyakutira, C. et al. High prevalence of the CYP2B6 516G-T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365 (2008).
10. Berwick, D.M. Disseminating innovations in health care. JAMA 289, 1969-1975 (2003).
11. Holford, N. & Karlsson, M.O. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin. Pharmacol. Ther. 82, 103-105 (2007).